1932

Abstract

Preclinical and clinical studies have clearly shown a benefit of nonsteroidal anti-inflammatory drug (NSAID) use in reducing cancer risk. However, the adverse gastrointestinal and cardiovascular side effects associated with NSAIDs and COX-2 selective inhibitors (coxibs) have provoked more scrutiny of the precise role of specific downstream mediators in the prostaglandin (PG) signaling cascade. NSAIDs and coxibs inhibit PG biosynthesis. One of the PGs produced at high levels in the tumor microenvironment is PGE, which is thought to play a major role in cancer progression. Thus, a better understanding of PGE signaling could enable identification of novel and safer therapeutic targets downstream of the cyclooxygenase enzymes. We review the emerging molecular mechanisms by which COX-2–derived PGE is involved in cancer progression and delineate potential opportunities for development of novel pharmacologic approaches utilizing this pathway.

Keyword(s): EP receptormPGESPDGHPGE2PGHS
Loading

Article metrics loading...

/content/journals/10.1146/annurev.med.57.121304.131253
2007-02-18
2024-12-06
Loading full text...

Full text loading...

/content/journals/10.1146/annurev.med.57.121304.131253
Loading
/content/journals/10.1146/annurev.med.57.121304.131253
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error